Bio-Gene Technology Capital Expenditures
The Capital Expenditures (CapEx) of Bio-Gene Technology (BGT.AX) as of Oct 11, 2026 is -1.94 M AUD.
Get this data via API
Financial Data API
Capital Expenditures
-1.94 MAUD
Last updated:
The Bio-Gene Technology Capital Expenditures history
3 Years
10 Years
25 Years
Max
| YEAR | Capital Expenditures | YoY |
|---|---|---|
| -1.94 MAUD | — | |
| 0.00AUD | -100.00% | |
| -5,698.00AUD | — | |
| 0.00AUD | -100.00% | |
| -6,840.00AUD | +125.82% | |
| -3,029.00AUD | 0.00% | |
| -3,029.00AUD | +12.94% | |
| -2,682.00AUD | -98.88% | |
| -239,496.00AUD | +4,704.33% | |
| -4,985.00AUD | -82.21% | |
| -28,020.00AUD | 0.00% | |
| -28,020.00AUD | +1,734.97% | |
| -1,527.00AUD | — |
Bio-Gene Technology Stock analysis
Frequently Asked Questions about Bio-Gene Technology stock
Capital Expenditures (CapEx) of Bio-Gene Technology is -1.94 M AUD in 2026.
On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Bio-Gene Technology since 2006 – with annual values, charts, and detailed analysis.
Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.
Capital Expenditures (CapEx)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Bio-Gene Technology historically and in real time.
Cash Flow — Bio-Gene Technology
All Key Metrics — Bio-Gene Technology
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth